[2-(4-Chloro-phenyl)-5-furan-2-yl-oxazol-4-yl]-acetyl chloride | 113598-18-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [2-(4-Chloro-phenyl)-5-furan-2-yl-oxazol-4-yl]-acetyl chloride
• 英文别名: 2-[2-(4-chlorophenyl)-5-(furan-2-yl)-1,3-oxazol-4-yl]acetyl chloride
• CAS: 113598-18-8
• 化学式: C₁₅H₉Cl₂NO₃
• 分子量: 322.147
• InChiKey: WNQRDVXQXSXYOF-UHFFFAOYSA-N

物化性质

• 沸点：
  477.7±55.0 °C(predicted)
• 密度：
  1.388±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.56
• 重原子数：
  21.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  56.24
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  正庚醇 、 [2-(4-Chloro-phenyl)-5-furan-2-yl-oxazol-4-yl]-acetyl chloride 反应 5.0h， 生成 n-heptyl 2-[2-(4-chlorophenyl)-5-(furan-2-yl)-4-oxazolyl]acetate
  参考文献：
  名称：

  Synthesis of ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate, a hypolipidemic agent, and related compounds

  摘要：

  A series of 2-aryl and 2-alkyl derivatives of 5-furyl-4-oxazoleacetic acid and their homologues having alkyl groups at the alpha-position of the acids were synthesized and evaluated for their hypolipidemic activities in Sprague-Dawley rats. On the basis of the structure-activity relationships and subacute toxicities, ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate (35) was selected as a candidate compound for development. Compound 35 reduced serum cholesterol and triglyceride levels by 23% and 35%, respectively, at a dose of 0.05% in a diet in normal rats, and it was about 10 times more active in hereditary hyperlipidemic rats (THLR/1) than in normal rats. Compound 35 inhibited platelet aggregation in vitro and also normalized hyperaggregability of hyperlipidemic plasma platelet ex vivo.

  DOI：

  10.1021/jm00401a021
• 作为产物：
  描述：

  乙基[2-(4-氯苯基)-5-(2-呋喃基)-1,3-恶唑-4-基]乙酸酯 在 吡啶 、 氢氧化钾 、 氯化亚砜 作用下， 以 甲醇 、 氯仿 、 水 为溶剂， 反应 8.0h， 生成 [2-(4-Chloro-phenyl)-5-furan-2-yl-oxazol-4-yl]-acetyl chloride
  参考文献：
  名称：

  Synthesis of ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate, a hypolipidemic agent, and related compounds

  摘要：

  A series of 2-aryl and 2-alkyl derivatives of 5-furyl-4-oxazoleacetic acid and their homologues having alkyl groups at the alpha-position of the acids were synthesized and evaluated for their hypolipidemic activities in Sprague-Dawley rats. On the basis of the structure-activity relationships and subacute toxicities, ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate (35) was selected as a candidate compound for development. Compound 35 reduced serum cholesterol and triglyceride levels by 23% and 35%, respectively, at a dose of 0.05% in a diet in normal rats, and it was about 10 times more active in hereditary hyperlipidemic rats (THLR/1) than in normal rats. Compound 35 inhibited platelet aggregation in vitro and also normalized hyperaggregability of hyperlipidemic plasma platelet ex vivo.

  DOI：

  10.1021/jm00401a021